Cell Line, Tumor

SEP 8, 2026 · JOURNAL ARTICLE

Thioredoxin reductase-1 facilitates cellular plasticity and stemness mediated by TGF-β1 in non-small cell lung cancer.

Cancer Biology & Therapy

Mechanistic study in cell lines and a mouse model identifying a pathway without clinical endpoint data or direct evidence of therapeutic benefit in humans.

JUL 30, 2026 · JOURNAL ARTICLE

Tuning optical properties, charge transfer and anticancer activity of curcumin-cyanine conjugates: A combined experimental and DFT study.

Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy

Early-stage structure-activity study of novel synthetic compounds with in vitro cytotoxicity data but no in vivo validation, mechanistic proof of PDT efficacy, or clinical translation.

JUL 23, 2026 · JOURNAL ARTICLE

A promising therapeutic strategy reduces abnormal Aβ deposition and inhibits neuronal apoptosis via FGF17 ameliorating AD-like neurodegeneration.

Brain Research

A mechanistic study in cell and transgenic mouse models showing FGF17 delivery reduces Aβ deposition and apoptosis with pathway confirmation, but lacking human efficacy data and powered clinical outcomes.

JUL 20, 2026 · JOURNAL ARTICLE

Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin.

Cancer Biology & Therapy

In vitro study demonstrates reversal of cisplatin resistance in one cell line via ALDH and ABCC2 inhibition, requiring validation in additional models and clinical testing.

JUN 25, 2026 · JOURNAL ARTICLE

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology

Preclinical mechanistic study identifying neutrophils as key regulators of vaccine-induced antitumor immunity with potential therapeutic implications, but requires clinical validation.

JUN 24, 2026 · JOURNAL ARTICLE

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.

Oncoimmunology

Preclinical evidence in a mouse model demonstrates that a sequenced triple regimen achieves high complete response rates, but findings are not yet clinically validated and lack quantitative efficacy metrics in the abstract.

JUN 22, 2026

KIF18A inhibitor prevents chromosomally unstable osteosarcoma growth by activating spindle assembly checkpoint.

Cancer Biology & Therapy

Preclinical cell-line and xenograft data showing anti-tumor activity of a KIF18A inhibitor in osteosarcoma models without human trial evidence.

JUN 15, 2026 · RESEARCH ARTICLE (MECHANISTIC)

STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis.

Cancer Biology & Therapy

Preclinical in vitro and mouse model evidence linking STARD10 to HER2+ breast cancer progression via lipid metabolism, without clinical efficacy data.